Structure via PubChem · Public domain (PubChem)
gliquidone
Sign in to saveAlso known as ARDF-26, Glurenorm
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
Chemical data
- Formula
- C27H33N3O6S
- Molecular weight
- 527.6 g/mol
- IUPAC name
- 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- diabetes mellitus
via ChEMBL · EBI
Research
187 papers- Gliquidone.Acta crystallographica. Section E, Structure reports online · 2011
- Gliquidone ameliorates hepatic insulin resistance in streptozotocin-induced diabetic Sur1(-/-) rats.European journal of pharmacology · 2021
- Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data.Drugs in R&D · 2006
- Gliquidone Alleviates Diabetic Nephropathy by Inhibiting Notch/Snail Signaling Pathway.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2018
- Inhibition of Cardiac Kv4.3/KChIP2 Channels by Sulfonylurea Drug Gliquidone.Molecular pharmacology · 2024
via PubMed
Wikidata facts
- Mass
- 527.209
Show 4 more facts
- chemical formula
- C₂₇H₃₃N₃O₆S
- World Health Organisation international non-proprietary name
- gliquidone
- canonical SMILES
- CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C
- defined daily dose
- 60
Sources (3)
via Wikidata · CC0
~1 min read
Article
3 sectionsContents
- Contraindications
- Pharmacokinetics
- References
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
==Contraindications== Allergy to sulfonylureas or sulfonamides Diabetes mellitus type 1 Diabetic ketoacidosis Patients that underwent removal of the pancreas Acute porphyria Severe liver disease accompanying with liver insufficiency Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required Pregnancy or breastfeeding
Available in 11 languages
via Wikidata sitelinks · CC0